NCT04702737 - A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 10, 2021

Primary Completion Date

July 22, 2024

Study Completion Date

July 22, 2024

Conditions

Neuroendocrine Prostate Cancer

Interventions

DRUG

Tarlatamab

Tarlatamab will be administered as an intravenous (IV) infusion.

Trial Locations (21)

2050

Chris OBrien Lifehouse, Camperdown

3000

Peter MacCallum Cancer Centre, Melbourne

4020

Ordensklinikum Linz Elisabethinen, Linz

5020

Landeskrankenhaus Salzburg, Salzburg

8036

Medizinische Universitaet Graz, Graz

9000

Universitair Ziekenhuis Gent, Ghent

10021

Weill Cornell Medical College, New York

27103

Wake Forest University Health Sciences, Winston-Salem

30322

Winship Cancer Institute of Emory University, Atlanta

43210

The Ohio State University, Columbus

46250

Community Health Network MD Anderson Cancer Center - North, Indianapolis

60637

University of Chicago, Chicago

77030

University of Texas MD Anderson Cancer Center, Houston

85054

Mayo Clinic Arizona, Phoenix

94158

University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco

94805

Gustave Roussy, Villejuif

63110-1093

Washington University, St Louis

160-8582

Keio University Hospital, Shinjuku-ku

3015 GD

Erasmus Medisch Centrum, Rotterdam

08036

Hospital Clinic i Provincial de Barcelona, Barcelona

SM2 5PT

Royal Marsden Hospital, Sutton